surmount-1 tirzepatide trial obesity without diabetes Effect of in trial. (BMI: body mass index; CI: Tirzepatide cuts diabetes risk by

Cost, Access, and Insurance Matter The medication that looks best on paper may not be the best option for a real patient if it is unaffordable or unavailable

You can read the full article at Tirzepatide, a new medication, has been approved in the United States for adults with type 2 diabetes as an additional treatment to diet and exercise

Diabetes beyond insulin: review of new drugs for treatment of diabetes mellitus

Tirzepatide is a glucagon-like peptide-1 (GLP-1) receptor agonist and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, which work together to improve blood sugar control and promote weight loss in patients with type 2 diabetes

Type 2 diabetes is the most common form of diabetes in which the body makes or uses insulin in an abnormal way, resulting in higher blood glucose levels